Press releases

3 November 2014

Verona Pharma announces Venture and Innovation Award from the Cystic Fibrosis Trust

Funds further studies exploring potential for RPL554 as a novel treatment for CF Verona Pharma first drug development company to receive Award 3 November 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicine…

Read more

29 September 2014

New data supports RPL554 as a potential novel cystic fibrosis therapy

29 September 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, reports that RPL554, the Company’s lead molecule, currently in phase 2 clinical development for the treat…

Read more

9 September 2014

RPL554 presentations at ERS Congress highlight its valuable potential in combination therapy for COPD and other respiratory diseases

9 Sept 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in- class medicines to treat respiratory diseases, announces that today two posters discussing the potential of RPL554 as a combination therapy with anticholinerg…

Read more

23 June 2014

Verona Pharma reports Phase IIa headline results for VRP700

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that the Phase IIa clinical trial, to evaluate the efficacy of a single dose of VRP700 as a novel treatment for chroni…

Read more

21 May 2014

Data highlighting synergistic action of novel dual PDE3/4 inhibitor RPL554 with muscarinic receptor antagonists and beta-adrenoceptor agonists in reversing bronchoconstriction presented at ATS international conference

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that a poster was presented on Tuesday 20 May as part of the scientific programme at American Thoracic Society (ATS) I…

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us